Inflammatory disease therapy by targeting NLRP3 inflammasome
The NLRP3 inflammasome is a key regulator of inflammatory diseases but lacks FDA-approved inhibitors.
Oxidized DNA (oxDNA) plays a crucial role in NLRP3 activation, and thus offers a new therapeutic target.
Repurposed glycosylase inhibitors block NLRP3 pyrin binding to oxDNA and reduce IL-1β secretion.
Structural analysis reveals shared active site features among NLRP3 inhibitors that will aid drug development.
Several NLRP3 inhibitors in clinical trials have potential applications in neurodegeneration, cancer, and metabolic diseases.
https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(25)00073-2
